Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2013 3
2014 1
2016 7
2017 2
2019 2
2020 3
2021 3
2022 3
2023 6
2024 6
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F. Van Gorp T, et al. Among authors: miller re. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. Lancet Oncol. 2025. PMID: 40179908 Clinical Trial.
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.
Kristeleit R, Devlin MJ, Clamp A, Gourley C, Roux R, Hall M, Nirsimloo R, Kounnis V, Sage L, Narayanan P, Herrington CS, Arora R, Farrelly L, Hughes L, Counsell N, Miller RE. Kristeleit R, et al. Among authors: miller re. JAMA Oncol. 2025 Apr 1;11(4):377-385. doi: 10.1001/jamaoncol.2024.6797. JAMA Oncol. 2025. PMID: 39913118 Free PMC article. Clinical Trial.
Targeted therapies in gynaecological cancers.
Crusz SM, Miller RE. Crusz SM, et al. Among authors: miller re. Histopathology. 2020 Jan;76(1):157-170. doi: 10.1111/his.14009. Histopathology. 2020. PMID: 31846530 Review.
The role of PARP inhibitor combination therapy in ovarian cancer.
Hockings H, Miller RE. Hockings H, et al. Among authors: miller re. Ther Adv Med Oncol. 2023 May 16;15:17588359231173183. doi: 10.1177/17588359231173183. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37215065 Free PMC article. Review.
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.
Yap TA, LoRusso P, Miller RE, Kristeleit R, Paulovich AG, McMorn S, Oplustil O'Connor L, Lombardi B, Marco-Casanova P, Gangl ET, Patel B, O'Connor MJ, Dean E, Zviezdin R, Plummer R. Yap TA, et al. Among authors: miller re. Br J Cancer. 2025 Aug;133(2):168-177. doi: 10.1038/s41416-025-03053-x. Epub 2025 May 17. Br J Cancer. 2025. PMID: 40382524 Free PMC article. Clinical Trial.
39 results